加强抗纤维化治疗：克服当前局限性的纳米医学方法
Enhancing anti-fibrotic therapy: nanomedicine approaches to overcome current limitations.
摘要(中文译文)
纤维化作为一种共同特征，在多种慢性疾病中普遍存在。然而，当前的抗纤维化药物治疗策略因靶向能力不足、全身毒性及生物利用度低等问题，在临床应用和疗效方面受到限制。纳米技术的出现开创了纤维化新型治疗策略的时代，彻底改变了治疗格局。本文系统综述了纳米材料在纤维化治疗中的双重应用：其一，作为纳米颗粒药物递送系统（NDDS）以增强靶向性、控制释放并提高药物生物利用度；其二，作为治疗剂直接缓解纤维化的发生与进展。此外，本文进一步讨论了具有多样化设计和组成的纳米材料在影响不同器官的纤维化中的应用。
Abstract
Fibrosis, as a shared hallmark, is prevalent in a variety of chronic diseases. However, current pharmacological strategies for fibrosis are limited in clinical application and efficacy due to issues such as insufficient targeting capability, systemic toxicity, and low bioavailability. The advent of nanotechnology has ushered in an era of novel therapeutic strategies for fibrosis, revolutionizing the treatment landscape. This article systematically reviews the dual applications of nanomaterials in fibrosis treatment: first, as nanoparticle drug delivery systems (NDDS) to enhance targeting, control release, and improve drug bioavailability; second, as therapeutic agents directly alleviating the onset and progression of fibrosis. Furthermore, this article further discusses the applications of nanomaterials with diverse designs and compositions in fibrosis affecting different organs.
如何引用
AMA
Lincan Wu, Xin Li, Lina Yang. Enhancing anti-fibrotic therapy: nanomedicine approaches to overcome current limitations.. Materials today. Bio. 2026; doi:10.1016/j.mtbio.2026.103253.
APA
Lincan Wu, Xin Li, Lina Yang (2026). Enhancing anti-fibrotic therapy: nanomedicine approaches to overcome current limitations.. Materials today. Bio. https://doi.org/10.1016/j.mtbio.2026.103253
GB/T 7714
Lincan Wu, Xin Li, Lina Yang. Enhancing anti-fibrotic therapy: nanomedicine approaches to overcome current limitations.[J]. Materials today. Bio, 2026 doi:10.1016/j.mtbio.2026.103253.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出